Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P42 vs Eylea in Diabetic Macular Edema
NCT04739306Phase 3Completed
- Sponsor
- Celltrion
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CT-P42 in diabetic macular edema (DME) (2 arms), sponsored by Celltrion. Primary endpoint: Mean Change From Baseline in Best Corrected Visual Acuity at Week 8. Started Jul 2021; status: completed.
02
Drugs
CT-P42
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04739306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739306.